Skip to content
No picture yet

Taro-Lenalidomide 2.5 mg – DIN 02507862

Taro-Lenalidomide is Lenalidomide 2.5 mg (capsule), sold in Canada. It is used for multiple myeloma and mantle-cell lymphoma. It is supplied by Taro Pharmaceuticals Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.

Sold in Canada

Lenalidomide 2.5 mg

Brand
Taro-Lenalidomide
Strength
2.5 mg
Used for
Multiple myeloma and mantle-cell lymphoma
Form
Capsule
Manufacturer
Taro Pharmaceuticals Inc
Drug class
Thalidomide analog
Sold in
Canada
DIN
02507862

Source: Health Canada's Drug Product Database. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Lenalidomide pills and guides

What is Lenalidomide used for?

Lenalidomide is used for multiple myeloma and mantle-cell lymphoma.

Medicine type
Thalidomide analog
Official uses from the US prescribing label

Multiple Myeloma

Lenalidomide capsules in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM).

Lenalidomide capsules are indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).

Myelodysplastic Syndromes

Lenalidomide capsules are indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Mantle Cell Lymphoma

Lenalidomide capsules are indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

Follicular Lymphoma

Lenalidomide capsules in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).

Marginal Zone Lymphoma

Lenalidomide capsules in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).

Limitations of Use

Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with CLL outside of controlled clinical trials.

From the FDA-approved label on DailyMed (published Sep 15, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your medicine? Check the box

  • The box or bottle shows DIN 02507862.
  • It names Taro-Lenalidomide, Lenalidomide 2.5 mg.
  • A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.

Sold in Canada as Taro-Lenalidomide by Taro Pharmaceuticals Inc.

In Canada: prescription only.

Ingredients

Active: Lenalidomide

Other Lenalidomide pills